Remdesivir [1809249-37-3]

Cat# HY-104077-10mg

Size : 10mg

Brand : MedChemExpress

Contact local distributor :


Phone : +1 850 650 7790

Remdesivir (GS-5734), un analogue nucléosidique avec une activité antivirale efficace, a des EC50s de 74 nM pour SARS-CoV et MERS-CoV dans les cellules AOH et 30 nM pour le virus de l'hépatite murine dans les cellules tumorales cérébrales retardées. Remdesivir est très efficace dans le contrôle de l’infection par le SRAS-CoV-2 (COVID-19) in vitro.

Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.

For research use only. We do not sell to patients.

Remdesivir Chemical Structure

CAS No. : 1809249-37-3

*

This product is a controlled substance and not for sale in your territory.

  • N Engl J Med. 2023 Jan 5;388(1):89-91.  [Abstract]
  • Cell Discov. 2022 Sep 9;8(1):89.  [Abstract]
  • Science. 2021 Nov 26;374(6571):1099-1106.  [Abstract]
  • Signal Transduct Target Ther. 2021 Feb 4;6(1):51.  [Abstract]
  • Nature. 2021 May;593(7859):418-423  [Abstract]
  • Signal Transduct Target Ther. 2021 Apr 24;6(1):165.  [Abstract]
  • Nature. 2020 Jun;582(7813):561-565.  [Abstract]
  • Science. 2020 Jun 26;368(6498):1499-1504.  [Abstract]
  • Cell Res. 2020 Mar;30(3):269-271.  [Abstract]
  • Nat Cell Biol. 2023 Aug;25(8):1223-1234.  [Abstract]
  • Nat Commun. 2023 Jul 4;14(1):3952.  [Abstract]
  • Nat Commun. 2023 Jul 15;14(1):4231.  [Abstract]
  • Sci Transl Med. 2022 Nov 3;eabq4064.  [Abstract]
  • J Extracell Vesicles. 2022 Jan;11(1):e12179.  [Abstract]
  • Nat Commun. 2021 Nov 5;12(1):6415.  [Abstract]
  • Nat Commun. 2021 Oct 4;12(1):5811.  [Abstract]
  • Nat Commun. 2021 Aug 9;12(1):4887.  [Abstract]
  • Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]
  • EBioMedicine. 2022 Jun 29;81:104132.
  • Biomaterials. April 2022, 121460.
  • Redox Biol. 2021 Sep;45:102041.  [Abstract]
  • Genes Dev. 2021 Jun 24.  [Abstract]
  • Acta Pharm Sin B. 2021 Mar 11.
  • Emerg Microbes Infect. 2021 Feb 4;1-38.  [Abstract]
  • Emerg Microbes Infect. 2021 Feb 9;1-32.  [Abstract]
  • Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121.  [Abstract]
  • J Med Virol. 2020 Aug 7.  [Abstract]
  • Cell Chem Biol. 2022 Jun 9;S2451-9456(22)00201-X.  [Abstract]
  • Cell Rep. 2021 Nov 23;37(8):110049.  [Abstract]
  • Cell Rep. 2021 Apr 6;35(1):108959.
  • Int J Biol Macromol. 2021 Jan 31;168:474-485.  [Abstract]
  • Int J Biol Sci. 2020 Oct 16;16(16):3100-3115.  [Abstract]
  • Antiviral Res. 2024 Mar 5:225:105856.  [Abstract]
  • Antiviral Res. 2023 Aug 8;105700.  [Abstract]
  • Antiviral Res. 2023 Jul 12;105671.  [Abstract]
  • Mbio. 2023 Jun 20;e0106023.  [Abstract]
  • Antiviral Res. 2023 May 3;214:105619.  [Abstract]
  • Antiviral Res. 2023 Apr 17;105606.  [Abstract]
  • Int J Nanomedicine. 2023 Mar 27.
  • Mbio. 2023 Feb 14;e0328522.  [Abstract]
  • Antiviral Res. 2022 Jun 19;204:105365.  [Abstract]
  • Arch Toxicol. 2022 May 17;1-20.  [Abstract]
  • PLoS Pathog. 2021 Sep 17;17(9):e1009929.  [Abstract]
  • Antiviral Res. 2021 Jul;191:105089.  [Abstract]
  • Eur J Med Chem. 2021, 113683.
  • Antiviral Res. 2021 Jan;185:104977.  [Abstract]
  • Bioeng Transl Med. 2020 Dec 1;6(1):e10196.  [Abstract]
  • Antiviral Res. 2020 Dec;184:104955.  [Abstract]
  • J Virol. 2024 Jan 18:e0121623.  [Abstract]
  • Sci Rep. 2023 Nov 17;13(1):20178.  [Abstract]
  • Virol Sin. 2023 Jul 3;S1995-820X(23)00079-2.  [Abstract]
  • Stem Cell Reports. 2023 Jun 13.
  • Antimicrob Agents Chemother. 2023 Mar 28;e0170322.  [Abstract]
  • J Antimicrob Chemother. 2023 Feb 10;dkad027.  [Abstract]
  • Virol J. 2023 Jan 31;20(1):18.  [Abstract]
  • Molecules. 2022 Dec 12;27(24):8829.  [Abstract]
  • Biosensors (Basel). 2022, 12(11): 950.
  • Comput Struct Biotechnol J. 2022 Aug 30.  [Abstract]
  • Viruses. 2022, 14(9), 2017.
  • Viruses. 2022, 14(7), 1369.
  • Commun Biol. 2022 Feb 22;5(1):154.  [Abstract]
  • Viruses. 2022 Feb 8;14(2):353.  [Abstract]
  • Biomolecules. 2021 Dec 10;11(12):1858.  [Abstract]
  • Sci Rep. 2021 Dec 6;11(1):23465.  [Abstract]
  • iScience. 2021 Dec 17;24(12):103412.  [Abstract]
  • Front Pharmacol. 2020 Jul 21;11:1091.  [Abstract]
  • Biomedicines. 2021, 9(11), 1725.
  • Pharmaceutics. 2021, 13(10), 1656.
  • iScience. 9 September 2021.
  • J Virol. 2021 Aug 11;JVI0064321.  [Abstract]
  • Biomedicines. 2021, 9(8), 996.
  • IUBMB Life. 2021 Aug 13.  [Abstract]
  • Microorganisms. 2021, 9(8), 1731.
  • mSphere. 2021 May 5;6(3):e00235-21.  [Abstract]
  • Viruses. 2021, 13(4), 610.
  • Viruses. 2021, 13(4), 558.
  • Microorganisms. 2021 Mar 31;9(4):734.  [Abstract]
  • Sci Rep. 2021 Mar 8;11(1):5433.  [Abstract]
  • Sci Rep. 2021 Mar 8;11(1):5376.  [Abstract]
  • Int J Mol Sci. 2021, 22(3), 1398.
  • Viruses. 2021 Feb 9;13(2):271.  [Abstract]
  • Biomed J. 2021 Jan 28.
  • Sci Rep. 2021 Jan 12;11(1):821.  [Abstract]
  • Viruses. 2020 Dec 5;12(12):1394.  [Abstract]
  • Microorganisms. 2020 Nov 26;8(12):1872.  [Abstract]
  • ACS Pharmacol Transl Sci. 2020 Oct 14;3(6):1278-1292.  [Abstract]
  • Sci Rep. 2020 Oct 1;10(1):16200.  [Abstract]
  • Viruses. 2020 Jun 10;12(6):628.  [Abstract]
  • Molecules. 2020 May 17;25(10):2343.  [Abstract]
  • Pharmaceuticals. 2020 Apr 10;13(4):65.  [Abstract]
  • Antivir Res. 2020 Jun;178:104786.  [Abstract]
  • Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20.  [Abstract]
  • PLoS One. 2022 Nov 10;17(11):e0276751.  [Abstract]
  • J Appl Toxicol. 2022 May 12.  [Abstract]
  • J Hum Lact. 2022 Feb 21;8903344221076539.  [Abstract]
  • Eur Rev Med Pharmacol Sci. 2021 Dec;25(1 Suppl):81-89.  [Abstract]
  • Clin Transl Sci. 2021 Nov 10.  [Abstract]
  • Clin Transl Sci. 2021 Oct 31.  [Abstract]
  • J Neural Transm (Vienna). 2021 Jul;128(7):1159-1168.  [Abstract]
  • Chem Pap. 2021 May 16.
  • J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Mar 10;1171:122641.  [Abstract]
  • Mol Divers. 2021 Jan 3;1-16.  [Abstract]
  • New J Chem. 2020 Oct 12.
  • J Gen Virol. 2020 Sep;101(9):925-940.  [Abstract]
  • bioRxiv. 2024 Mar 1.
  • Preprints. 2024 Feb 19.
  • bioRxiv. 2024 Jan 6.
  • Preprints. 2024 Jan 3.
  • SSRN. 2024 Jan 26.
  • bioRxiv. 2023 Nov 21.
  • Patent. US20230312571A1.
  • University of California. 2023 Jun.
  • SSRN. 2023 Mar 30.
  • Front Drug Discov. 2023 Jan 5.
  • Research Square Preprint. 2023 Apr 5.
  • Patent. US20230123135A1.
  • bioRxiv. 2023 Mar 9.
  • Utah State University. 2023 Feb 1.
  • bioRxiv. 2023 Feb 24.
  • Ruprecht Karls University. The Faculty of Bio Sciences.
  • Patent. US20220389050A1.
  • Patent. US20220380769A1.
  • Patent. US20220339140A1.
  • Patent. US20220339132A1.
  • Patent. US20220288080A1.
  • Preprints. 2022, 2022070375.
  • Curr Res Virol Sci. 2022;3:100019.  [Abstract]
  • bioRxiv. January 10, 2022.
  • bioRxiv. January 03, 2022.
  • Patent. US20210379058A1.
  • The University of Texas Southwestern Medical Center. Human Pathophysiology and Translational. December, 2021.
  • Patent. US20210346411A1.
  • bioRxiv. 2021 Mar 25;2021.03.25.437060.  [Abstract]
  • Research Square Preprint. 2021 Aug.
  • Patent. US20210220377A1.
  • bioRxiv. 2021 Aug 10;2021.08.06.455494.  [Abstract]
  • Phytomedicine Plus. 2021, 100058.
  • Research Square Preprint. 2021 Feb;17(2):e10188.  [Abstract]
  • Research Square Preprint. 2020 Oct 7;rs.3.rs-86169.  [Abstract]
  • Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.
  • ChemRxiv. 2020 Jun.
  • bioRxiv. 2020 May.
  • F1000Research. 2020 May.
  • bioRxiv. 2020 Apr. 
  • bioRxiv. 2020 Mar.
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.

EC50: 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell)
EC50: 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta)

In Vitro

Remdesivir (GS-5734) inhibits murine hepatitis virus (MHV) with an EC50 of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC50s of both 74 nM in HAE cells after treatment for 24 h.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

  • [1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18.  [Content Brief]

    [2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.  [Content Brief]

    [3]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054.  [Content Brief]

  • [1]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18.

    [2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

    [3]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054.

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6595 mL 8.2977 mL 16.5953 mL 41.4883 mL
5 mM 0.3319 mL 1.6595 mL 3.3191 mL 8.2977 mL
10 mM 0.1660 mL 0.8298 mL 1.6595 mL 4.1488 mL
15 mM 0.1106 mL 0.5532 mL 1.1064 mL 2.7659 mL
20 mM 0.0830 mL 0.4149 mL 0.8298 mL 2.0744 mL
25 mM 0.0664 mL 0.3319 mL 0.6638 mL 1.6595 mL
30 mM 0.0553 mL 0.2766 mL 0.5532 mL 1.3829 mL
40 mM 0.0415 mL 0.2074 mL 0.4149 mL 1.0372 mL
50 mM 0.0332 mL 0.1660 mL 0.3319 mL 0.8298 mL
60 mM 0.0277 mL 0.1383 mL 0.2766 mL 0.6915 mL
80 mM 0.0207 mL 0.1037 mL 0.2074 mL 0.5186 mL
100 mM 0.0166 mL 0.0830 mL 0.1660 mL 0.4149 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Cell Cycle/DNA Damage Anti-infection
  • DNA/RNA Synthesis SARS-CoV
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Remdesivir1809249-37-3GS-5734GS5734GS 5734DNA/RNA SynthesisSARS-CoVSARS coronavirusantiviralMERS-CoV2019-nCoVCOVID-19infectionInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Bulk Inquiry

Inquiry Information

Product Name:
Remdesivir
Cat. No.:
HY-104077
Quantity:
MCE Japan Authorized Agent:

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
A17170-10
 10mg 
A17170-5
 5mg 
A17170-2
 2mg